- Home
- DNP vs ACLX Comparison
DNP vs ACLX Comparison
Compare DNP & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$69.53
Company Overview
Basic Information| Metric | DNP | ACLX |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.2B |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | DNP | ACLX |
|---|---|---|
| Price | $10.05 | $69.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $115.50 |
| AVG Volume (30 Days) | 479.6K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 7.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.30 | N/A |
| Revenue | ★ $154,887,179.00 | $35,898,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $302.49 |
| P/E Ratio | $4.26 | ★ N/A |
| Revenue Growth | ★ 3.30 | N/A |
| 52 Week Low | $8.69 | $47.86 |
| 52 Week High | $10.04 | $94.07 |
Technical Indicators
Market Signals| Indicator | DNP | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 46.06 | 33.01 |
| Support Level | $10.00 | $66.00 |
| Resistance Level | $10.35 | $75.03 |
| Average True Range (ATR) | 0.11 | 5.23 |
| MACD | -0.02 | -1.69 |
| Stochastic Oscillator | 14.29 | 12.96 |
Price Performance
Historical Comparison DNP
ACLX
About DNP DNP Select Income Fund Inc.
DNP Select Income Fund Inc is a closed-ended investment management fund. The primary investment objectives of the fund are current income and long-term growth of income. Its secondary objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing in the public utility industry.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.